1. Home
  2. CXM vs TYRA Comparison

CXM vs TYRA Comparison

Compare CXM & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprinklr Inc.

CXM

Sprinklr Inc.

N/A

Current Price

$6.64

Market Cap

1.6B

Sector

Technology

ML Signal

N/A

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

N/A

Current Price

$20.98

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CXM
TYRA
Founded
2009
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
CXM
TYRA
Price
$6.64
$20.98
Analyst Decision
Hold
Strong Buy
Analyst Count
9
15
Target Price
$8.44
★ $47.64
AVG Volume (30 Days)
★ 2.2M
563.9K
Earning Date
12-02-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.05
N/A
Revenue
★ $857,200,000.00
N/A
Revenue This Year
$1.19
N/A
Revenue Next Year
$3.46
N/A
P/E Ratio
$130.40
★ N/A
Revenue Growth
★ 7.64
N/A
52 Week Low
$4.72
$14.67
52 Week High
$8.28
$40.65

Technical Indicators

Market Signals
Indicator
CXM
TYRA
Relative Strength Index (RSI) 58.52 48.31
Support Level $5.18 $18.46
Resistance Level $7.03 $22.37
Average True Range (ATR) 0.21 1.08
MACD -0.04 0.16
Stochastic Oscillator 37.40 33.22

Price Performance

Historical Comparison
CXM
TYRA

About CXM Sprinklr Inc.

Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale, all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights, and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: